MHRA approves oral Wegovy as NPA flags counterfeit risk
The MHRA has approved a pill form of Wegovy for use in the UK, marking a significant regulatory development for one of the most high-profile weight loss medicines on the market. The National Pharmacy Association responded by raising concerns that an oral version of the medicine may be easier to counterfeit than its injectable counterpart.
What happened
The MHRA granted approval for an oral version of Wegovy — the semaglutide-based weight loss medicine — allowing it to be legally marketed in the UK. Despite the regulatory green light, the pill is not currently available on the NHS.
Following the announcement, the NPA publicly flagged a specific concern: that a pill form of the medicine could present a greater counterfeiting risk than the injectable version. The concern reflects broader anxieties about the integrity of supply chains for weight loss medicines, which have attracted intense public demand in recent years.
Why it matters
Semaglutide has dominated pharmacy headlines for some time now, and not always for straightforward reasons. Supply pressures, unlicensed products, and questions about patient safety have all featured. The MHRA approval of an oral formulation adds another layer to a story that community pharmacists — and those training to become one — need to keep up with.
The NPA's counterfeiting concern is worth sitting with. Counterfeit medicines are a genuine patient safety risk, and the worry here isn't abstract. Injectable medicines require specific equipment, cold chain handling, and specialist packaging that adds friction for anyone trying to produce a fake. A pill is simpler to manufacture and far harder for a patient to distinguish from a legitimate product by looking at it. That's the logic behind the NPA's concern, and it's the kind of thinking pharmacy professionals are expected to apply.
For a pre-reg candidate, this story touches on several threads that run through pharmacy practice. Medicines authentication, the role of the MHRA in licensing decisions, and the responsibilities pharmacists carry when dispensing or advising on medicines that attract high demand — these are all areas where the gap between passing an exam and practising safely is narrower than it looks.
The fact that the pill is approved but not currently available on the NHS also matters. Patients who want access to a licensed oral semaglutide product may seek it through private routes, including online pharmacies. Pharmacists working in those settings — or advising patients who ask — need to be clear on the difference between a licensed medicine and an unlicensed or counterfeit one, and on what their professional obligations are when something doesn't look right.
Counterfeiting of high-demand medicines is not a hypothetical. When a medicine becomes publicly associated with significant weight loss, demand outstrips supply and that gap creates opportunity for illegitimate products to enter circulation. The oral format concern raised by the NPA reflects this pattern. Pills can be manufactured without specialised equipment, packaged to look like legitimate products, and sold through unregulated online channels to patients who have no way of verifying what they're receiving.
Pharmacists act as the last line of defence here in a very practical sense. They're trained to identify packaging irregularities, question provenance, and know when to refuse to dispense. That's not a ceremonial function — it's a clinical one.
GPhC exam relevance
The GPhC Common Registration Assessment tests applied knowledge, and medicines safety sits squarely within that scope. A few areas connect directly to this story.
Medicines legislation in the UK draws a clear line between licensed and unlicensed products, and between legitimate supply chains and falsified ones. Candidates are expected to understand what a marketing authorisation means, what the MHRA's role is in granting it, and what obligations fall on pharmacists when handling or advising on medicines — particularly those that are high-demand or high-risk.
Patient safety scenarios in the assessment often involve recognising when something is wrong with a product or a supply situation. The thinking the NPA is applying to oral semaglutide — asking whether the format creates new risks — is exactly the kind of professional reasoning the GPhC expects registrants to demonstrate.
The assessment also covers professional and ethical decision-making. If a patient presents a prescription for a medicine that's hard to source through legitimate channels, or asks about a product they've obtained online, the pharmacist's responsibilities don't disappear because the conversation is inconvenient. Knowing when to raise a concern, who to raise it with, and how to document it are all part of the competency framework.
Medicines with high public interest tend to generate exam-relevant scenarios. GLP-1 medicines have been in that category for a while. The approval of an oral formulation adds a new dimension — questions about the difference between routes of administration, the significance of a new marketing authorisation, and the patient safety implications of oral versus injectable delivery are all fair territory.
What's next
The immediate question for NHS patients is access. The approval exists, but NHS availability does not — at least not yet. Watch for any NICE guidance or NHS commissioning decisions that follow the MHRA approval, as those will determine whether and when the oral formulation reaches NHS prescribing.
For private and online pharmacy channels, the approval matters now. Pharmacies operating in those spaces will need to have clear processes for verifying product legitimacy and managing demand in a way that puts patient safety first.
The NPA's counterfeiting concern is likely to prompt further discussion within the sector. Whether that leads to specific guidance for pharmacists, changes to how the medicine is classified or controlled, or action from regulators on supply chain monitoring remains to be seen. Keep an eye on updates from the MHRA and professional bodies over the coming weeks.
If you're in your pre-reg year, this is also a good moment to revisit the legal framework around medicines supply — specifically the provisions that govern what pharmacists must do when they have reason to doubt a product's legitimacy. That knowledge is testable, and this story is a practical illustration of why it matters.
Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/news/regulation/significant-mhra-approves-wegovy-pill-for-use-in-the-uk-KVCI7KHLM5DNXHWOSEHXR6666Y/